Table 1.
Patient characteristics prior to denosumab treatment.
| Characteristic | Denosumab (n = 22) | Combination (n = 21) | p-Value |
|---|---|---|---|
| Age (years) | 72.3 ± 2.0 | 72.1 ± 2.7 | 0.94 |
| Gender (F:M) | 20:2 | 18:3 | |
| BMI (kg/m2) | 21.8 ± 0.9 | 21.5 ± 0.7 | 0.74 |
| Serum-corrected calcium (mg/dL) | 9.2 ± 0.1 | 9.1 ± 0.1 | 0.19 |
| Serum phosphorus (mg/dL) | 3.7 ± 0.1 | 3.5 ± 0.2 | 0.40 |
| Serum BAP (μg/L) | 21.4 ± 2.3 | 22.1 ± 2.5 | 0.85 |
| TRACP-5b (mU/dL) | 595.1 ± 45.7 | 593.4 ± 49.2 | 0.98 |
| Urinary NTX (nmol BCE/mmol CRE) | 52.6 ± 5.6 | 49.7 ± 5.6 | 0.67 |
| 1,25(OH)2D3 (pg/mL) | 57.9 ± 4.7 | 57.6 ± 6.7 | 0.97 |
| Serum whole PTH (pg/mL) | 28.9 ± 2.8 | 30.0 ± 2.8 | 0.77 |
| Lumbar 1–4 BMD (g/cm2) | 0.789 ± 0.02 | 0.798 ± 0.04 | 0.84 |
| Total hip BMD (g/cm2) | 0.657 ± 0.02 | 0.672 ± 0.03 | 0.68 |
BMI: body mass index; BAP: bone specific alkaline phosphatase; TRACP-5b: tartrate-resistant acid phosphatase-5b; NTX: N-terminal telopeptide of type-I collagen; PTH: parathyroid hormone; BMD: bone mineral density. Results are the mean ± standard error of the mean. A P-value of < 0.05 was considered statistically significant.